Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group (Q31976463)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

0 references

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

author name string

Einhorn D

1

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Rendell M

2

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Rosenzweig J

3

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Egan JW

4

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Mathisen AL

5

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Schneider RL

6

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

publication date

1 December 2000

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

1395-1409

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

New drug overview. Pioglitazone hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms and clinical effects of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The homeostasis model in the San Antonio Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma lipids and diabetes mellitus in an adult community

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of dyslipidemia in adults with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983039-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(00)83039-8

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31976463&oldid=1909610658"